CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms
The current clinical JAK2 inhibitors are type I kinase inhibitors that provide clinical benefits to myeloproliferative neoplasm (MPN) patients but do not reduce mutant allele burden. Meyer et al. report a type II JAK2 inhibitor that shows activity against relevant MPN models and reduces mutant allele burden.